The serum levels of immunosuppressive acid protein (IAP) and CA 125 were determined in 98 patients with ovarian cancer, in 20 patients with benign ovarian tumors and in a group of normal postmenopausal women as controls. On the basis of the mean values of normal controls (346.46 ± 133.26 μg/ml), the IAP threshold was fixed at 613 ∣ig/ml. Increased IAP levels were found in 70.4% of patients with ovarian cancer, in 25% of benign tumors and in 4.5% of normal women. Elevated levels of CA 125 were observed in 66.6% of cancers, in 40% of benign tumors and in 6.9% of controls. In particular, in early stage ovarian cancer the combined assay of the two markers increased by about 30% with respect to CA 125 alone. The simultaneous determination of IAP and CA 125 allowed an overall sensitivity of 84% without any significant reduction of specificity.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.